Salute e Benessere

Clarivate Identifies Radioligand Therapy Innovators as Companies to Watch in the…

Radioligand therapies represent one of the most promising frontiers in oncology, offering highly specific delivery of radioactive isotopes to tumor cells while minimizing damage to healthy tissue. These agents are rapidly gaining momentum as both scientific breakthroughs and strategic investments accelerate across the global pharmaceutical landscape. Radioligand therapies represent one of the most promising frontiers in oncology, offering highly specific delivery of radioactive isotopes to...
PR Newswire
16/06/2025

Zentiva acquires heritage brands from Aboca to expand natural-based Consumer…

The acquisition reinforces Zentiva's ambition to become a leading Consumer Healthcare (CHC) player. While the deal has a particular emphasis on the markets in Italy, Spain and France, its scope also covers other countries including Portugal, Poland, Romania, and Greece. The acquisition reinforces Zentiva's ambition to become a leading Consumer Healthcare (CHC) player. While the deal has a particular emphasis on the markets inItaly,SpainandFrance, its scope also covers other countries...
PR Newswire
16/06/2025

Canadian hospital system leverages Sectra's AI service to enhance patient care…

"With Sectra Amplifier Services, we have the opportunity to transform our everyday workflows and consistently deliver high-quality, people-centered care across our facilities. We are excited to grow our partnership with Sectra as we embark on this new journey together," says David Stankiewicz, Vice President, Digital Transformation and Chief Information & Privacy Officer at William Osler Health System. "With Sectra Amplifier Services, we have the opportunity to transform our…
PR Newswire
16/06/2025

Bracco Imaging and Subtle Medical Announce CE Mark of AiMIFY™ Software for…

"We are proud to extend our successful partnership with Subtle Medical into the European market," said Sascha Daeuber, Radiology Platform Leader at Bracco Imaging. "From the beginning, Subtle has proven to be an agile and visionary partner—our joint announcement of FDA clearance last year underscored that strength. With the CE Mark for AiMIFY, we're taking the next step in our shared mission to deliver innovative, AI-powered solutions that enhance diagnostic precision and support…
PR Newswire
16/06/2025

Roche to advance prasinezumab into Phase III development for early-stage…

Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson’s diseasePrasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progressionParkinson's disease affects over 10 million people globally and significant unmet need remainsBasel, 16 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today its decision to...
Nasdaq GlobeNewswire
16/06/2025

ArkBio's New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted…

Azstarys (AK0901) is the first and currently the sole globally approved ADHD combination therapeutic pairing immediate-release dexmethylphenidate (d-MPH) with the prodrug serdexmethylphenidate (SDX). Approved by the U.S. FDA in 2021, Azstarys represents a new generation of methylphenidate medications, providing a dual-phase release profile that offers both rapid onset and sustained symptom control. This novel formulation sets a new benchmark in the management of ADHD for safety, efficacy, and…
PR Newswire
16/06/2025

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab)…

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory studyNew late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair in improving such key signs and symptoms as nasal polyp size and sense of smell in...
Nasdaq GlobeNewswire
15/06/2025

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates…

Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE ®NHL-2 trial show investigational treatment with epcoritamab in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) led to an overall response rate (ORR) of 87 percent and a complete response (CR) rate of 65 percent in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Data further demonstrates the potential of epcoritamab in combination with salvage...
Nasdaq GlobeNewswire
15/06/2025

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on…

After a thorough clinical review, the benefit-risk for the use of Elevidys in non-ambulatory patients with Duchenne has been re-assessed, following two cases of fatal acute liver failureEffective immediately, dosing of non-ambulatory patients, irrespective of age, is paused in the clinical setting; dosing of non-ambulatory patients is discontinued in the commercial setting Roche is working closely with relevant health authorities, investigators and prescribing physicians to ensure...
Nasdaq GlobeNewswire
15/06/2025

Cold Storage Market Size & Share Report - 2034

The global cold storage market size was accounted at USD 165.62 billion in 2024 and is projected to surpass around USD 445.81 billion by 2034, growing at a compound annual growth rate (CAGR) of 10.41% over the forecast period 2025 to 2034.
Cervicorn Consulting
14/06/2025

Innocan Pharma Highlights Breakthrough Narrative Review on Liposomal Synthetic…

Chronic pain affects over 24% of adults in the United States alone, placing a significant burden on patients, healthcare systems, and economies*. Yet, long-term treatment options remain inadequate. NSAIDs pose cumulative toxicity risks, and opioids—while effective—present serious concerns including tolerance, dependency, and overdose risk. Globally, opioid misuse results in over 100,000 deaths annually (DOI: 10.1016/j.lana.2023.100557). Chronic pain affects over 24% of adults inthe United...
PR Newswire
13/06/2025

KFSHRC Advances Smart Hospital Transformation through AI and Emerging…

RIYADH, Saudi Arabia, June13, 2025(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) continues to redefine global healthcare through its Smart Hospital initiative, leveraging AI, simulation, and immersive technologies across its departments. These technologies have supported KFSHRC to enhance workforce training, clinical care, and operational efficiency.The Academic & Training Affairs (ATA) division is leading this transformation, deploying...
Nasdaq GlobeNewswire
13/06/2025

Groupe Casino - Nombre de droits de vote et d'actions 31-05-2025

CASINO, GUICHARD-PERRACHON Société anonyme au capital de 4 009 397,13 € Siège social : 1, Cours Antoine Guichard 42000 Saint-Etienne 554 501 171 R.C.S. Saint-Etienne Informations relatives au nombre total de droits de vote et d'actions composant le capital social au 31 mai 2025(article 223-16 du Règlement Général de l'Autorité des Marchés Financiers)Nombre d'actions composant le capitalNombre total de droits de voteNombre total de droits de vote exerçables en...
Nasdaq GlobeNewswire
13/06/2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2025

AggregatedpresentationbydayandbymarketStatement of transactions in own shares from June 2nd to June 6th 2025 Name of the issuerIdentity code of the issuer(Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)IPSEN549300M6SGDPB4Z94P1102/06/2025FR0010259150 ...
Nasdaq GlobeNewswire
13/06/2025

PolTREG Establishes U.S. Subsidiary Immuthera to Advance International…

PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy PolTREG established Immuthera (https://immuthera.bio/) in Delaware to expand its presence in the U.S. market. A Pre-IND application was submitted to the FDA.The Paediatric Committee (PDCO) of the European Medicines Agency issued a positive opinion on PolTREG's Pediatric Investigation Plan (PIP) for PTG-007 in pre-symptomatic type 1 diabetes (Stage 1). Gdańsk,...
Nasdaq GlobeNewswire
13/06/2025

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab…

TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that dosing has commenced at the prestigious Weill Cornell Medicine Multiple Sclerosis Center in New York City, in its ongoing Phase 2 clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS)...
Nasdaq GlobeNewswire
13/06/2025

Diagnostic Electrocardiograph/ECG Market worth US$15.18 billion by 2032 with…

Browse in-depth TOC on "Diagnostic Electrocardiograph/ECG Market" Browse in-depth TOC on "Diagnostic Electrocardiograph/ECG Market" 150 - Tables 60 - Figures 250 - Pages By Product,the diagnostic ECG market is categorized into diagnostic ECG devices and diagnostic ECG software & services, with the diagnostic ECG devices segment commanding the largest market share. This predominance is attributable to the critical role these devices play in routine cardiac diagnostics,...
PR Newswire
13/06/2025

Revolutionizing Diagnostics: Digital Pathology Market Growth Report | Reach…

For More Information and To Stay Updated on The Latest Developments in The Global Digital Pathology Market, Download FREE Sample Pages: https://www.theresearchinsights.com/request_sample?id=9996 For More Information and To Stay Updated on The Latest Developments in The Global Digital Pathology Market, Download FREE Sample Pages: https://www.theresearchinsights.com/request_sample?id=9996 Market Overview and Growth Trajectory: Digital Pathology Market Growth: According to...
PR Newswire
13/06/2025

IoT Medical Devices Market worth US$154.74 billion by 2030 with 18.9% CAGR |…

Browse in-depth TOC on "IoT Medical Devices Market" Browse in-depth TOC on "IoT Medical Devices Market" 299 - Tables 57 - Figures 329- Pages By Based on type,Stationary medical devices are a key segment of the IoT medical devices market, driven by the growing demand for continuous monitoring, real-time data analysis, and enhanced patient care in healthcare facilities. Devices such as IoT-integrated imaging systems, smart infusion pumps, and diagnostic equipment facilitate...
PR Newswire
13/06/2025

Tiziana Life Sciences to Present at the Bio International Convention

TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its CEO, Ivor Elrifi, will be giving an oral presentation during the Bio International Convention in Boston, MA. Mr Elrifi's presentation will cover the recent clinical findings of Tiziana's lead drug candidate, intranasal foralumab. Foralumab is the first...
Nasdaq GlobeNewswire
13/06/2025

OptiGroup acquires Technotape B.V. in the Netherlands

For further information, please contact:Alex de Graaf, SVP, OptiGroup, [email protected] Sikander, Corporate Communication Director, OptiGroup, [email protected] For further information, please contact: Alex de Graaf, SVP, OptiGroup,[email protected] Sikander, Corporate Communication Director, OptiGroup,[email protected] This information was brought to you by Cisionhttp://news.cision.com. https://news.cision...
PR Newswire
13/06/2025

Exhale Wellness Launches Its THCa Flower 2025 Lineup

Known for its unique ability to offer non-psychoactive benefits in its raw form and psychoactive effects when heated, THCa flower continues to gain momentum among both wellness-focused consumers and recreational users seeking an alternative to traditional THC products. Known for its unique ability to offer non-psychoactive benefits in its raw form and psychoactive effects when heated, THCa flower continues to gain momentum among both wellness-focused consumers and recreational users seeking…
PR Newswire
13/06/2025

AccuStem Sciences, Inc. Announces Chairman Purchase of Shares

About AccuStem AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. We plan to drive innovation in healthcare by offering proprietary molecular testing that addresses unmet clinical needs from cancer screening through treatment and monitoring. By interrogating novel disease pathways, such as tumor “stemness,” we believe our tools will help care teams better understand the biology of each patient's cancer,...
Nasdaq GlobeNewswire
13/06/2025

Keymed Biosciences Announces the Latest Clinical Trial Results of CM336…

The overall study showed that CM336 had demonstrated positive efficacy signals in treating patients with relapsed/refractory AIHA who had previously received multiple therapies, with rapid disease control and sustained remission lasting over half a year, while also exhibiting good safety profile, potentially making it an innovative treatment option for development in this disease. The overall study showed that CM336 had demonstrated positive efficacy signals in treating patients with...
PR Newswire
13/06/2025
Altri  Comunicati